Friday, 12 June 2020

Male Breast Cancer Industry Overview By Growth Factors, Product Chain Value, Competitors Analysis And Forecast 2023

Market Scenario

The global male breast cancer market growth is expected to increase slowly at a CAGR of ~ 3.6% during the forecast period from 2018 to 2023. Male breast cancer is caused when the breast tissues of males start growing out of control and become cancerous.
Numerous factors such as increasing obese population and growing geriatric population are expected to drive the growth of the market. For instance, in July 2017, the Bristol-Myers Squibb Company announced a broad clinical collaboration with Clovis Oncology for evaluating the combination of cancer drugs Nivolumab and Rucaparib in Phase 2 and Phase 3 clinical trials in multiple tumor types.
Moreover, favorable healthcare expenditures boost the growth of the market. However, lack of knowledge and the high cost of treatments may hamper the market growth during the assessment period.
Segmentation
The global male breast cancer market has been segmented into type, diagnosis, and treatment.
The market, on the basis of type, has been segmented into, ductal carcinoma in situ, Paget’s disease of the nipple, inflammatory breast cancer, and infiltrating ductal carcinoma.
The market, by diagnosis, has been segmented into, mammography, biopsy, PET scan, CT scan, MRI scan, and other tests. On the basis of diagnosis, biopsy is anticipated to record the largest growth owing to its accuracy of diagnosing the disease. It is also expected to be the fastest growing segment.
By diagnosis, biopsy is further segmented into, fine needle aspiration biopsy, core biopsy, and excisional biopsy.
The market, by treatment, has been segmented into, local treatments and systemic treatments.
By treatment, local treatments are further segment into, surgery and radiation therapy.
Surgery is further segmented into, mastectomy, breast-conserving surgery, and lymph nodes biopsy.
By treatment, systemic treatments are further segmented into, chemotherapy, hormone therapy, and targeted therapy.
Chemotherapy is further segmented into, adjuvant therapy and neoadjuvant therapy.
Hormone therapy is further segmented into, using drugs and orchiectomy (castration).
Targeted therapy is further segmented into, for HER2 positive breast cancer, for hormone receptor-positive breast cancer, and for cancer with BRCA mutations.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The male breast cancer market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European male breast cancer market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
The male breast cancer market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The male breast cancer market in the Middle East and Africa has been segmented into the Middle East and Africa.
Key players
Achieve Life Sciences, Inc., Pfizer, Eli Lilly and Company, Bristol-Myers Squibb Company, F. Hoffmann-La Roche, Sanofi, Novartis AG, BioNumerik Pharmaceuticals Inc., Seattle Genetics, Inc., GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., AstraZeneca, Accord Healthcare, and Bayer AG are some of the key players in the global male breast cancer market.
Regional Market Summary
Global Male Breast Cancer Market Share (%), by Region, 2017
Source: World Health Organization (WHO), Centers for Disease Control and Prevention (CDC)
Geographically, the Americas is anticipated to dominate the global male breast cancer market owing to the changing lifestyle and rising prevalence of breast cancer. According to an article published by, the American Cancer Society in April 2018, the lifetime risk of getting breast cancer in men is approximately 1 in 833. Europe is expected to hold the second largest position in the global male breast cancer market. The market growth in this region is attributed to the growing prevalence of rare cancers, the availability of funds for research, and increasing healthcare expenditure. According to the Cancer Research UK, 371 new cases of male breast cancer were reported in 2015 in the UK.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the rising awareness regarding early symptoms of cancer and government support for healthcare facilities. According to a study published by the European Society for Medical Oncology in January 2016, there were 4.3 million new cases of cancer in China in 2015.
On the other hand, the Middle East and Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle Eastern region due to growing government initiatives for the healthcare sector.

Posted by at No comments:

Worldwide Endovascular Aneurysm Repair Devices Market Witness A Remarkable Growth Projected By 2023

Market Scenario

Global endovascular aneurysm repair devices market is likely to grow significantly over the forecast period. It is estimated that the global endovascular aneurysm repair devices market is expected to record a CAGR ~ 6.4 % during the forecast period of 2018 to 2023. The weakening and bulging of the aorta is called aortic aneurysm. The bulging can cause a leak that spills blood into the body. It can direct the blood flow away from the organs and tissues, causing severe complications, such as kidney damage, heart attacks, stroke, and even death. Thus, endovascular repair can be done by placing a stent-graft in an aneurysm through a small hole in the blood vessels in the groin area.
Numerous factors such as reduced recovery times, low-cost hospitalization charges, and technological advancements in repair devices are expected to drive the growth of the endovascular aneurysm repair devices market trends. For instance, in March 2017, Terumo Corporation completed the acquisition of Bolton Medical, Inc. with the acquired company being a leading innovator in thoracic and abdominal stent graft systems, Terumo Corporation aimed to strengthen its growth in vascular graft segment.
However, stringent government regulation, the preferable alternative of open surgery and various complications such as endoleaks and infections may hamper the market growth during the assessment period.
Segmentation
The global endovascular aneurysm repair devices market has been segmented into indication, site, anatomy, and products.
The market, on the basis of indication, has been segmented into the abdominal aortic aneurysm, thoracic aortic aneurysm and others.
The market, based on thoracic aortic aneurysm, has been further segmented into ascending aortic aneurysm, descending aortic aneurysm, thoracoabdominal aortic aneurysm, and thoracic arch aortic aneurysm.
The market, on the basis of the site, has been segmented into infrarenal and pararenal.
The market, based on pararenal site, has been sub-segmented into juxtarenal and suprarenal.
The market, on the basis of anatomy, has been segmented into traditional and complex.
The market, on the basis of products, has been segmented into percutaneous EVAR, fenestrated EVAR, aortic stents and TAA grafts, and others.
Key players
Cardiatis SA, Cardinal Health, Cook Medical LLC, Endologix, INC., Jotec GmbH, Medtronic plc, Terumo Corporation, W. L. Gore & Associates, Inc., BiFlow Medical Ltd, Boston Scientific Corporation, Braile Biomédica, Endoluminal Sciences Pty Ltd, Endospan Ltd., Getinge AB, and Lemaitre Vascular Inc. are some of the key players in the global endovascular aneurysm repair devices market.
Regional Market Summary
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The endovascular aneurysm repair devices market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European endovascular aneurysm repair devices market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
The endovascular aneurysm repair devices market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The endovascular aneurysm repair devices market in the Middle East and Africa has been segmented into the Middle East, and Africa.
The Americas is expected to dominate the global endovascular aneurysm repair devices market owing to increasing geriatric population, and well-developed healthcare sector. With the increase in the geriatric population, the prevalence of aneurysms is also expected to rise. The Centers for Disease Control and Prevention (CDC) ranks abdominal aortic aneurysm as one of the top 15 causes of mortality in the United States, but only for those between 85 and 89 years. According to the Centers for Disease Control and Prevention, aortic aneurysms were the primary cause of 9,863 deaths in 2014 in the US.
Europe is expected to hold the second largest position in the global endovascular aneurysm repair devices market. The market growth in this region is attributed to the growing prevalence of aneurysms, availability of funds for research, and favorable reimbursement scenario.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population and continuously developing economies.
On the other hand, the Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to the growing government initiatives for the healthcare sector.
Posted by at No comments:

Malaria Diagnostics Market Innovative Treatments, Key Methodologies, Size, Growth, Top Players Success Milestones And Forecasts To 2023

The Global Malaria Diagnostics Market Expected to Garner a CAGR of 4.63% During the assessment period between 2018 and 2023. It is reported in Malaria Diagnostics Market analysis released by Market Research Future (MRFR), that the market is positively influenced by a number of factors.
Malaria is a serious life-threatening disease caused by a parasite, transmitted by the bite of infected anopheles mosquitoes. Infected mosquitoes transport the Plasmodium parasite. When the infected mosquito bites you, the parasite is released into your bloodstream. Once the human body becomes the host for the parasite it travels to the liver and matures. After some days, the mature parasite enters the bloodstream and starts to infect red blood cells (RBC). Humans suffering from malaria frequently experience fever, headache, weakness, vomiting
A major factor influencing this growth is the increasing advancements in technology related to diagnostic tools and the proliferating demand for such treatments in malaria-endemic countries. Other factors driving the market growth are rising support from the government in terms of investment funds and an increase in the collaboration between the research centers and the industry. Malaria diagnostic tests play a significant role in identifying malarial cases, which thereby boosts the growth of the overall malaria diagnostic market trends and size.
However, the lack of precise monitoring standards at developing nations, acts as a major factor constraining the market. The lack of awareness among emerging nations and work regulatory framework is of particular concern for both manufacturers and healthcare providers.
Key Players
Some of the key players in the global malaria diagnostics market are Access Bio. Inc., Abbott Laboratories, Premier Medical Corporation Pvt. Ltd, Sysmex Partec GmbH, bioMérieux, Beckman Coulter Inc., Siemens Healthineers, Leica Microsystems GmbH, Nikon Corporation, Olympus Corporation, and Bio-Rad Laboratories Inc.
Segmentation
The global malaria diagnostics market has been segmented on the basis of technology and end-user.
On the basis of technology, the market has been classified as rapid diagnostic tests, microscopy, and molecular diagnostic tests. The molecular diagnostics tests are segmented into polymerase chain reaction (PCR) and real-time polymerase chain reaction (RT-PCR).
On the basis of end-users, the market has been classified as hospitals, clinics, community healthcare, and others.
On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada.
The European malaria diagnostics market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
The malaria diagnostics market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The malaria diagnostics market in the Middle East and Africa has been segmented into the Middle East and Africa. 
Regional Market Summary
In the malaria diagnostics market, North America is anticipated to account for the largest market share due to the early adoption of advanced medical technologies, the rise in awareness, the rise in growth of the healthcare sector, and due to favorable compensation setting for many surgical procedures. In 2016, global governments of malaria-endemic countries have invested USD 2.7 billion in malaria control and elimination efforts. The US was the largest contributor by providing USD 1 billion for the eradication of malaria.
The European market is expected to hold the least share due to the growing number of malaria-free countries in the region.
The market in the Middle East and Africa is expected to account for the smallest share of the global malaria diagnostics market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities. Sub-Saharan Africa remains to bring an excessively high share of the global malaria burden on the Middle Eastern and African market. the region was home to 90% of malaria incidences and 92% of malaria deaths in 2015
The market share in Asia-Pacific is also projected to experience growth in the near future due to access to optimal treatment facilities and growing demand for advanced technology, better adoption rate, increase in disposable income, and rising medical tourism. The Asia-Pacific remains to be the second largest burden of malaria globally with 22 malaria-endemic countries accounting for roughly 28 million cases and 45,000 deaths every year. The WHO figures say that in the Asia-Pacific region, Myanmar, Pakistan, India, and Indonesia carry the highest malaria burden accounting for 89% of all malaria cases in the region.
Posted by at No comments:

Thursday, 11 June 2020

Keratoconus treatment Market 2019 – Leading Manufactures, Regions, Drivers, Analysis And Forecasts Till 2023

Market Scenario:
The Global Keratoconus Treatment Market has been evaluated as a rapidly growing market and it is expected to continue growing in the near future.
Approximately 3 million people are affected by this disease across the globe. Advanced diagnostic and treatment options are key drivers for this market. Increasing awareness of the disease, increasing funding for R&D and growing demand from emerging regions such as Asia are major driving forces of the market. Major players of this market are investing in R&D to develop effective solution for keratoconus. Introduction of wide range of lenses is important factor for market growth.
The market for keratoconus treatment was around USD 322.7 million in 2016 and is expected to reach USD 427.5 million by 2023 which is a projected CAGR of 4.1%.
Keratoconus KC is a condition of the eye which results in liberal thinning of the cornea. This may result in blurry vision, double vision, near sightedness, astigmatism, and light sensitivity. Usually both eyes are affected. In more severe cases a scarring or a circle may be seen within the cornea. While the cause is unknown, it is thought to occur due to a combination of genetic, environmental, and hormonal factors.
Further about seven percent of those affected have a family history of the condition, proposed environmental factors comprise of rubbing eyes and allergies. The fundamental mechanism involves changes of the cornea to a cone shape. Diagnosis is by examination with a slit lamp.
Moreover initially the condition can typically be corrected with glasses or soft contact lenses. As the disease worsens special contact lenses may be required. In most people the disease stabilizes after a few years without severe vision problems. In a small number of Keratoconus KC is a condition of the eye which results in liberal thinning of the cornea. This may result in blurry vision, double vision, near sightedness, astigmatism, and light sensitivity. Usually both eyes are affected. In more severe cases a scarring or a circle may be seen within the cornea. While the cause is unknown, it is thought to occur due to a combination of genetic, environmental, and hormonal factors.
Key Players for Global Keratoconus Treatment Market:                               
Some of the key players in this market are: Bausch & Lomb Incorporated (US), CIBA VISION (US), CooperVision (US), HOYA Vision Care (Singapore), Johnson & Johnson Vision Care, Inc. (US), Menicon Co., Ltd. (Japan), Novartis AG (Switzerland), Optik Seis (Indonesia), and SAFILENS S.R.L. (Italy), and others.
Segmentations:                                                                                                                                        
Global keratoconus treatment market has been segmented on the basis of type which comprises of forme fruste keratoconus, corneal hydrops, keratoglobus, pellucid marginal degeneration, posterior keratoconus, and others.
On the basis of end user, it is segmented into eye hospitals & clinics, medical research centers, academic institutes, and others.
On the basis of diagnosis, the market is segmented into computerized corneal mapping, keratometry, slit-lamp examination, refraction test, and others. Slit-lamp examination includes tonometry, vision testing, and others.
On the basis of treatments, the market has been segmented into lenses, surgery, collagen cross-linking, and others. Lenses is sub-segmented into eyeglasses or soft contact lenses, hard contact lenses, piggyback lenses, hybrid lenses, scleral lenses, and others. Surgery is sub-segmented into corneal inserts, cornea transplant, and others. Collagen cross-linking is still in research process and more study is required to implement this treatment option.
Regional Analysis
Considering the global scenario of the market, America is the highest revenue generator with North American region contributing the most. North America mainly includes US and Canada. US is one of the dominant markets not only in America but also in the global market. European market is the second largest and UK is believed to be the fastest growing market for keratoconus treatment in this region. Increasing awareness, growing purchasing power, and rapidly improving healthcare sector are driving the growth for Asia Pacific keratoconus market. Asia Pacific is one of the high potential market for keratoconus treatment. Due to slow adoption of new treatments and prosucts, Middle East and Africa is expected to grow at steady pace.
Posted by at No comments:

Mitochondrial Myopathies Market Professional Overview 2019-2023 With Major Vendors Size, Shares And Worldwide Demand

Market scenario:
The growing number of m mitochondrial myopathy invalids is likely to spur the global mitochondrial myopathies market growth over the forecast period. The major issue with mitochondrial myopathies is that, it is a genetic disorder and till today, has no proper cure. This, is observed to generate boundless scope for research. The strong support of governments, across the world, is encouraging researchers for undertaking numerous research and developmental projects to develop effective treatment for mitochondrial myopathies. Hence, this factor can cast a positive influence on the mitochondrial myopathies market growth. The availability of certain diagnostic aids for the mitochondrial myopathies and their precise results are also expected to amplify the market growth. The presence of reimbursement and medical insurance policies for rare genetic diseases like mitochondrial myopathies can rise the profit margins of the mitochondrial myopathies market.
However, the unavailability of specific treatment regime for mitochondrial myopathies and lack of cognisance of the availability of enhanced diagnostic solutions for detecting mitochondrial myopathies are certain factors, which can interfere the mitochondrial myopathies market expansion.
The Mitochondrial Myopathies is expected to reach $ 600 million by the end of 2023, this market is projected to growing at a CAGR of ~ 3.2 % during 2017-2023.
Top-Notch Key Players                                         
MRFR profiled eminent companies which are operating in the global mitochondrial myopathies market. They are; Khondrion BV, Reata Pharmaceuticals, Inc., GeneDx, Stealth BioTherapeutics, NeuroVive Pharmaceutical AB, Centogene AG, and Raptor Pharmaceutical Corp.
Segments:
Type, diagnostic tests, and therapies are segments, under which the global mitochondrial myopathies market has been studies.
Based on the type, the mitochondrial myopathies market has been segmented into Mitochondrial encephalomyopathy, Kearns-Sayre syndrome (KSS), Pearson syndrome, Mitochondrial DNA depletion syndrome (MDS), Leigh syndrome, Myoclonus epilepsy with ragged red fibers (MERRF), Progressive external ophthalmoplegia (PEO), Mitochondrial neuro-gastrointestinal encephalomyopathy (MNGIE), and Neuropathy, ataxia and retinitis pigmentosa (NARP).
Based on therapies, the mitochondrial myopathies market has been segmented into vitamins, coenzymes and antioxidants, supportive, dietary, and other.
Based on diagnostic aids, the mitochondrial myopathies market has been segmented into genetic test, muscle biopsy, and blood enzyme test.
Regional analysis
Based on the region, the global mitochondrial myopathies market has been studied across North America, Asia Pacific, Europe, the Middle East Asia and Africa.
The US in North America, is to hold the largest share of the regional market, while, North America dominates the global mitochondrial myopathies market. The strong economy empowering North America is likely to bolster the market growth over the assessment period. Furthermore, the increasing number of screening tests is also expected to escalate the US market growth. To illustrate, in the U.S., the new-born screening is performed on a infant, despite, its parent’s health insurance status or ability to bear medical expenses or charged minimum for the testing. The expansion of mitochondrial myopathies patient pool and surge in the government support for research and development undertakings are other factors, which can drive up the American mitochondrial myopathies market. Continuous technical upgradation backing medical advancements are identified to spur the South American mitochondrial myopathies market. The existence of private health insurance plans like Medicaid and the Children's Health Insurance Program (CHIP) and likely to cast a positive impact on the regional mitochondrial myopathies market expansion.
The Asia Pacific region is to exhibit a fast-paced growth for the mitochondrial myopathies market. Emerging economies like India and China are likely to witness a considerable market growth due to the rising need to meet the existing medical backlogs.  However, owing to political loopholes and fragile economic condition in the Africa, the market can experience a stagnancy in the growth over the review period. But, the mitochondrial myopathies market is expected to be led by the Gulf nations, particularly Saudi Arabia and UAE.
Posted by at No comments:

Wound Closure Device Industry Growth, Trends And Forecast Till 2023 By Marketresearchfuture.Com

Market Scenario:
The timely treatment of wounds has progressed to incorporate non-invasive, disposable, and sterile wound closure solutions. Reports that assess the healthcare industry have been presented by Market Research Future, which creates reports on numerous industry verticals that examine the market progress and forecasts. The market is anticipated to accomplish a CAGR of 6.9 % in the forecast period.
The development of medical devices and treatment procedures for trauma-related injuries is motivating the wound closure device market. The rise in the volume of surgical procedures has increased the wound closure device market growth considerably. The upswing in the cases of trauma, burns, and accidents is stimulating the market for wound closure devices.
Moreover, advancement in technology, decrease in a number of surgical site infections and attempts to reduce hospital stays for reducing surgical expenditure is contributing to the growth of the market. According to a survey conducted by the American Professional Wound Care Association (2017), chronic nonhealing wounds impact nearly 15% of Medicare beneficiaries (8.2 million). The estimated spending for primary wound diagnosis is USD 28 billion per year and the cost for secondary wound diagnosis is estimated to be USD 31.7 billion.  
The risk associated with infectious wounds, side effects of wound closure devices, and unfavorable reimbursement policies may hamper the growth of the market during the assessment period.
Key Players
  • 3M,
  • Abbott Laboratories,
  • Braun Melsungen AG,
  • Ethicon Inc.,
  • ,
  • Smith & Nephew,
  • Baxter International,
  • BSN medical Inc.,
  • Derma Sciences,
  • Kinetic Concepts,
  • ConvaTec,
  • DACH Medical Group,
  • Arthrex GmbH,
  • Gecko Biomedical,
  • Integra LifeScience,
  • CP Medical.
Segmentation
The global wound closure device market has been segmented based on device, application, type of wound, and end-user.
On the basis of device, the market has been classified into adhesives, staples, sutures, and mechanical wound closure devices. Adhesives are furthers classified into fibrin tissue adhesives and cyanoacrylates. The sutures segment has been further divided into absorbable, non- absorbable, braided, and monofilament.
On the basis of application, the market has been classified into burns, ulcers, surgical wounds, pressure ulcers, diabetic ulcers, and arterial ulcers. On the basis of type, the surgical wounds segment has been sub-segmented into chronic wounds, acute wounds, and others.
The market, by end-user, has been segmented into hospitals, community healthcare service providers, ambulatory surgical centers, and home care.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The wound closure device market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European wound closure device market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
The wound closure device market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.
The wound closure device market in the Middle East and Africa has been segmented into the Middle East and Africa.
Regional Market Summary
The Americas is likely to hold the majority of the global wound closure device market owing to increase in the number of surgical procedures, increasing injuries related to accidents, sports and adventure, aging population, the presence of a well-established healthcare system, and adoption and awareness of the wound closure technology. According to the American Association for the Surgery of Trauma, injury accounts for over 150,000 deaths and over 3 million non-fatal injuries are reported per year in the US.
The European market is expected to be the second-largest wound closure device market after the Americas. The market growth in this region can be attributed to an increase in aged population and rising occurrence of sports injuries and accidents. Moreover, the growing number of road accidents in the European region are contributing to the growth of the market in this region. According to data published by the European Commission in 2018, more than 135,000 people suffered serious injury from road accidents.
Asia-Pacific is expected to be the fastest-growing wound closure device market during the forecast period owing to the significant increase in aged population, increasing prevalence of chronic diseases such as diabetes leading to the increasing cases of diabetic foot ulcer. According to WHO, there are more than 96 million diabetics patients in the Asia-Pacific region.
The market in the Middle East and Africa is expected to account for the smallest share of the global wound closure device market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.
Posted by at No comments:

Stroke Disorder & Treatment Market Size Estimation By Top Manufacturer, Latest Trends And Global Industry Forecast 2019 To 2023

Market Scenario
The Global Stroke Disorder and Treatment Market is presumed to demonstrate a healthy CAGR during the forecast period (2016-2022) owing to the rising high blood pressure patients, asserts Market Research Future (MRFR).
Heart problems and brain problems are considered among most dangerous medical problems, and their treatments are considered to be most expensive. Heart strokes and brain strokes can strike any moment and can be fatal. Hence, the market offering treatment for it is always lucrative. Globally it is increasing rapidly. The major factor that drives the growth of this market is the increasing high blood pressure patients. Due to increasing alcoholism and patients with diabetes, cardiovascular diseases are increasing the growth of this disorder and the market offering its treatment.
Stroke is referred to as the condition which occurs when clot is formed in the artery and oxygen supply is cut off. Brain cells thus get deprived of oxygen and start to die. Heart and brain strokes can strike any moment and can be fatal. Stroke is considered as one of the leading causes of death across the world with higher prevalence in the geriatric population.
Competitive Dashboard
  • AstraZeneca (U.K),
  • Bayer Pharma AG (Germany),
  • Novartis AG (Switzerland),
  • Daiichi Sankyo (Japan),
  • Pfizer (U.S).
Drivers and Constraints Impacting the Market
With increasing consumption of alcohol and diabetic patients, the global stroke disorder and treatment market is likely to flourish. Also, the increasing prevalence of cardiovascular diseases is highly influencing the market across the globe. Brain problems and heart problems are considered as the most dangerous medical issues across the world with expensive medication and treatments. Thus, the market offering treatment for it is lucrative. The market is further accelerated by the huge patient pool along with rising geriatric population across the globe. Moreover, atrial fibrillation, hypertension, and coronary heart diseases are contributing to the growth of the market.
On the flip side, high cost of treatment adversely affects the growth of the market. Moreover, the lack of transparent reimbursement scenario is also likely to dampen the stroke disorder and treatment market during the assessment period.
Global Stroke Disorder and Treatment Market: Segmental Analysis
The global stroke disorder and treatment market has been segmented on the basis of type, medicine, treatment, and region.
By mode of type, the global stroke disorder and treatment market has been segmented into ischemic stroke and hemorrhagic strokes. Among these, the weakened blood vessel leakage is referred to as hemorrhagic stroke. Ischemic stroke generally occurs due to an obstruction within a blood vessel which supplies blood to the brain.
By mode of medicine, the global stroke disorder and treatment market has been segmented into anticoagulants/antiplatelet, anti-hypertensive.
By mode of treatment, the global stroke disorder and treatment market has been segmented into tissue plasminogen activator (TPA), carotid endarterectomy, surgical treatment, endovascular procedures, and others. TPA is referred to as an enzyme involved in the breakdown of blood clots and dissolves them. It is a less invasive procedure and is used for treating problems affecting the blood vessels like aneurysm.
Regional Insights
Geographically, the stroke disorder and treatment market span across regions namely, Europe, North America, Asia Pacific, and Rest-of-the-World.
Among these, the North America region is presumed to dominate the stroke diagnostics and therapeutics market and is likely to maintain its dominance. The growth is attributed to the rising awareness among the population regarding the symptoms of stroke followed by the several harmful effects associated with high glucose level in blood. With technological advancements and high-end research, and rising public interest, the demand for stroke disorder and treatment is likely to trigger in the coming years. Moreover, encouraging healthcare infrastructure and higher healthcare expenditure are some of the major factors contributing to the growth of the stroke disorder and treatment market.
European holds the second-largest position with high diabetic population. Moreover, the growing percentage of diabetes mellitus population is directly proportionate to the associated risk of stroke in individuals, thereby contributing to the market growth during the assessment period. Additionally, technological advancements and healthcare research are further influencing the market growth.
Industry Updates
CERENOVUS business has recently launched the single largest global registry, the EXCELLENT Registry, in order to collect and analyze stroke-inducing blood clots removed from the brain with its EMBOTRAP II Revascularization Device. The EXCELLENT Registry is likely to enroll up to 1000 ischemic stroke patients in as many as 50 clinical sites in Europe and the United States.
Posted by at No comments:
Subscribe to: Posts (Atom)